浙江临床医学
浙江臨床醫學
절강림상의학
ZHEJIANG CLINICAL MEDICAL JOURNAL
2013年
3期
298-300
,共3页
马玉霞%郝增涛%祝啸先%李晨
馬玉霞%郝增濤%祝嘯先%李晨
마옥하%학증도%축소선%리신
子宫内膜癌%Survivin%环氧化酶%预后
子宮內膜癌%Survivin%環氧化酶%預後
자궁내막암%Survivin%배양화매%예후
Endometrial cancer%Survivin%COX-2
目的研究子宫内膜癌Survivin和COX-2的表达及与肿瘤级别和预后的关系.方法免疫组化法检测62例子宫内膜癌患者瘤组织Survivin和COX-2的表达,并对Survivin和COX-2的表达与子宫内膜癌的分级特征及患者生存时间进行统计分析.结果 Survivin和COX-2在子宫内膜癌中表达阳性率分别为82.3%,61.3%.子宫内膜癌的表达阳性率在不同FIGO分期及病理分级中的差异有统计学意义(P<0.05).Kps评分≤70分的患者子宫内膜癌的阳性率显著高于Kps评分>70分的患者(P<0.05).Survivin和COX-2表达阳性患者生存时间显著优于表达阴性的患者(P<0.05).结论 Survivin和COX-2在子宫内膜癌中高表达,可作为子宫内膜癌负性预后因子.
目的研究子宮內膜癌Survivin和COX-2的錶達及與腫瘤級彆和預後的關繫.方法免疫組化法檢測62例子宮內膜癌患者瘤組織Survivin和COX-2的錶達,併對Survivin和COX-2的錶達與子宮內膜癌的分級特徵及患者生存時間進行統計分析.結果 Survivin和COX-2在子宮內膜癌中錶達暘性率分彆為82.3%,61.3%.子宮內膜癌的錶達暘性率在不同FIGO分期及病理分級中的差異有統計學意義(P<0.05).Kps評分≤70分的患者子宮內膜癌的暘性率顯著高于Kps評分>70分的患者(P<0.05).Survivin和COX-2錶達暘性患者生存時間顯著優于錶達陰性的患者(P<0.05).結論 Survivin和COX-2在子宮內膜癌中高錶達,可作為子宮內膜癌負性預後因子.
목적연구자궁내막암Survivin화COX-2적표체급여종류급별화예후적관계.방법면역조화법검측62례자궁내막암환자류조직Survivin화COX-2적표체,병대Survivin화COX-2적표체여자궁내막암적분급특정급환자생존시간진행통계분석.결과 Survivin화COX-2재자궁내막암중표체양성솔분별위82.3%,61.3%.자궁내막암적표체양성솔재불동FIGO분기급병리분급중적차이유통계학의의(P<0.05).Kps평분≤70분적환자자궁내막암적양성솔현저고우Kps평분>70분적환자(P<0.05).Survivin화COX-2표체양성환자생존시간현저우우표체음성적환자(P<0.05).결론 Survivin화COX-2재자궁내막암중고표체,가작위자궁내막암부성예후인자.
Objective To explore the relationship between the expression of Survivin,COX-2 and pathological grade of endometrial cancer and prognosis. Methods Immunohistochemistry was used to detect the expressions of Survivin and COX-2 in 62 cases of endometrial cancer. Analysis the relationship between the expression of Survivin,COX-2 and pathological grade of endometrial cancer and prognosis. Results The positive expression reates of Survivin and COX-2 were 82.3%and 61.3%. The difference of Survivin and COX-2 positive rates in FIGO stage and several pathological grades were significant(P<0.05). Survivin and COX-2 positive rates of Kps≤70 group were higher than Kps>70 group. The survival time of Survivin and COX-2 positive patients were longer than negative patients(P<0.05). Conclusion Survivin and COX-2 were over expression in endometrial cancer. They can be serve as negative prognosis factor.